|
1
|
Waks AG and Winer EP: Breast cancer
treatment: A review. JAMA. 321:288–300. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Iancu G, Serban D, Badiu CD, Tanasescu C,
Tudosie MS, Tudor C, Costea DO, Zgura A, Iancu R and Vasile D:
Tyrosine kinase inhibitors in breast cancer (review). Exp Ther Med.
23(114)2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ding S, Sun X, Lu S, Wang Z, Chen X and
Shen K: Association of molecular subtype concordance and survival
outcome in synchronous and metachronous bilateral breast cancer.
Breast. 57:71–79. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Howlader N, Altekruse SF, Li CI, Chen VW,
Clarke CA, Ries LA and Cronin KA: US incidence of breast cancer
subtypes defined by joint hormone receptor and HER2 status. J Natl
Cancer Inst. 106(dju055)2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Howlader N, Cronin KA, Kurian AW and
Andridge R: Differences in breast cancer survival by molecular
subtypes in the United States. Cancer Epidemiol Biomarkers Prev.
27:619–626. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Pallerla S, Abdul AURM, Comeau J and Jois
S: Cancer vaccines, treatment of the future: With emphasis on
HER2-positive breast cancer. Int J Mol Sci. 22(779)2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Takada M and Toi M: Neoadjuvant treatment
for HER2-positive breast cancer. Chin Clin Oncol.
9(32)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Choong GM, Cullen GD and O'Sullivan CC:
Evolving standards of care and new challenges in the management of
HER2-positive breast cancer. CA Cancer J Clin. 70:355–374.
2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hesson LB, Cooper WN and Latif F: The role
of RASSF1A methylation in cancer. Dis Markers. 23:73–87.
2007.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Li M, Wang C, Yu B, Zhang X, Shi F and Liu
X: Diagnostic value of RASSF1A methylation for breast cancer: A
meta-analysis. Biosci Rep. 39(BSR20190923)2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Thaler S, Schmidt M, Schad A and Sleeman
JP: RASSF1A inhibits estrogen receptor alpha expression and
estrogen-independent signalling: Implications for breast cancer
development. Oncogene. 31:4912–4922. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Roßwag S, Sleeman JP and Thaler S:
RASSF1A-mediated suppression of estrogen receptor alpha
(ERα)-driven breast cancer cell growth depends on the Hippo-kinases
LATS1 and 2. Cells. 10(2868)2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Sun W, Shi Q, Zhang H, Yang K, Ke Y, Wang
Y and Qiao L: Advances in the techniques and methodologies of
cancer gene therapy. Discov Med. 27:45–55. 2019.PubMed/NCBI
|
|
15
|
Hong R and Xu B: Breast cancer: An
up-to-date review and future perspectives. Cancer Commun (Lond).
42:913–936. 2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Sun W, Liu XY, Ma LL and Lu ZL: Tumor
targeting gene vector for visual tracking of Bcl-2 siRNA
transfection and anti-tumor therapy. ACS Appl Mater Interfaces.
12:10193–10201. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Montaño-Samaniego M, Bravo-Estupiñan DM,
Méndez-Guerrero O, Alarcón-Hernández E and Ibáñez-Hernández M:
Strategies for targeting gene therapy in cancer cells with
tumor-specific promoters. Front Oncol. 10(605380)2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Altwaijry N, Somani S and Dufès C:
Targeted nonviral gene therapy in prostate cancer. Int J
Nanomedicine. 13:5753–5767. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Chen C, Yue D, Lei L, Wang H, Lu J, Zhou
Y, Liu S, Ding T, Guo M and Xu L: Promoter-operating targeted
expression of gene therapy in cancer: Current stage and prospect.
Mol Ther Nucleic Acids. 11:508–514. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hurst HC: Update on HER-2 as a target for
cancer therapy: The ERBB2 promoter and its exploitation for cancer
treatment. Breast Cancer Res. 3:395–398. 2001.PubMed/NCBI View
Article : Google Scholar
|
|
21
|
Cui X, Chen H, Zhang Q, Xu M, Yuan G and
Zhou J: Exploration of the structure and recognition of a
G-quadruplex in the her2 proto-oncogene promoter and its
transcriptional regulation. Sci Rep. 9(3966)2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lundgren K, Holm C and Landberg G: Hypoxia
and breast cancer: Prognostic and therapeutic implications. Cell
Mol Life Sci. 64:3233–3247. 2007.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wu D, Potluri N, Lu J, Kim Y and
Rastinejad F: Structural integration in hypoxia-inducible factors.
Nature. 524:303–308. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH
and van de Vijver MJ (eds): WHO classification of tumors of the
breast. 4th edtion. Lyon, IARC Press, 2012.
|
|
25
|
You D, Wang D, Liu P, Chu Y, Zhang X, Ding
X, Li X, Mao T, Jing X, Tian Z and Pan Y: MicroRNA-498 inhibits the
proliferation, migration and invasion of gastric cancer through
targeting BMI-1 and suppressing AKT pathway. Human Cell.
33:366–376. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Luo M, Hou L, Li J, Shao S, Huang S, Meng
D, Liu L, Feng L, Xia P, Qin T and Zhao X: VEGF/NRP-1axis promotes
progression of breast cancer via enhancement of
epithelial-mesenchymal transition and activation of NF-κB and
β-catenin. Cancer Lett. 373:1–11. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Chen N, He S, Geng J, Song ZJ, Han PH, Qin
J, Zhao Z, Song YC, Wang HX and Dang CX: Overexpression of
Contactin 1 promotes growth, migration and invasion in Hs578T
breast cancer cells. BMC Cell Biol. 19(5)2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhou PH, Zheng JB, Wei GB, Wang XL, Wang
W, Chen NZ, Yu JH, Yao JF, Wang H, Lu SY and Sun XJ:
Lentivirus-mediated RASSF1A expression suppresses aggressive
phenotypes of gastric cancer cells in vitro and in vivo. Gene Ther.
22:793–801. 2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
He S, Sun XJ, Zheng JB, Qi J, Chen NZ,
Wang W, Wei GB, Liu D, Yu JH, Lu SY and Wang H: Recombinant
lentivirus with enhanced expression of caudal-related homeobox
protein 2 inhibits human colorectal cancer cell proliferation in
vitro. Mol Med Rep. 12:1838–1844. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kreutzfeldt J, Rozeboom B, Dey N and De P:
The trastuzumab era: Current and upcoming targeted HER2+ breast
cancer therapies. Am J Cancer Res. 10:1045–1067. 2020.PubMed/NCBI
|
|
32
|
Murthy RK, Loi S, Okines A, Paplomata E,
Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, et
al: Tucatinib, trastuzumab, and capecitabine for HER2-positive
metastatic breast cancer. N Engl J Med. 382:597–609.
2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Tesch ME and Gelmon KA: Targeting HER2 in
breast cancer: Latest developments on treatment sequencing and the
introduction of biosimilars. Drugs. 80:1811–1830. 2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Arabi F, Mansouri V and Ahmadbeigi N: Gene
therapy clinical trials, where do we go? An overview. Biomed
Pharmacother. 153(113324)2022.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Dastjerd NT, Valibeik A, Rahimi Monfared
S, Goodarzi G, Moradi Sarabi M, Hajabdollahi F, Maniati M, Amri J
and Samavarchi Tehrani S: Gene therapy: A promising approach for
breast cancer treatment. Cell Biochem Funct. 40:28–48.
2022.PubMed/NCBI View
Article : Google Scholar
|
|
36
|
Xu Y, Hou J, Liu Z, Yu H, Sun W, Xiong J,
Liao Z, Zhou F, Xie C and Zhou Y: Gene therapy with tumor-specific
promoter mediated suicide gene plus IL-12 gene enhanced tumor
inhibition and prolonged host survival in a murine model of Lewis
lung carcinoma. J Transl Med. 9(39)2011.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Fang L, Shanqu L, Ping G, Ting H, Xi W, Ke
D, Min L, Junxia W and Huizhong Z: Gene therapy with RNAi targeting
UHRF1 driven by tumor-specific promoter inhibits tumor growth and
enhances the sensitivity of chemotherapeutic drug in breast cancer
in vitro and in vivo. Cancer Chemother Pharmacol. 69:1079–1087.
2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Alekseenko IV, Pleshkan VV, Sass AV,
Filyukova OB, Snezhkov EV and Sverdlov ED: A universal
tumor-specific promoter for cancer gene therapy. Dokl Biochem
Biophys. 480:158–161. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Liu Q, Kulak MV, Borcherding N, Maina PK,
Zhang W, Weigel RJ and Qi HH: A novel HER2 gene body enhancer
contributes to HER2 expression. Oncogene. 37:687–694.
2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Choe SS and Kim JB: Hypoxia-inducible
factors: New strategies for treatment of obesity-induced metabolic
diseases. Postgrad Med J. 96:451–452. 2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Shibata T, Giaccia AJ and Brown JM:
Development of a hypoxia-responsive vector for tumor-specific gene
therapy. Gene Ther. 7:493–498. 2000.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Zheng J, He S, Qi J, Wang X, Yu J, Wu Y,
Gao Q, Wang K and Sun X: Targeted CDX2 expression inhibits
aggressive phenotypes of colon cancer cells in vitro and
in vivo. Int J Oncol. 51:478–488. 2017.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Zhu S, Ying Y, Ye J, Chen M, Wu Q, Dou H,
Ni W, Xu H and Xu J: AAV2-mediated and hypoxia response
element-directed expression of bFGF in neural stem cells showed
therapeutic effects on spinal cord injury in rats. Cell Death Dis.
12(274)2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Zhu S, Ying Y, He Y, Zhong X, Ye J, Huang
Z, Chen M, Wu Q, Zhang Y, Xiang Z, et al: Hypoxia response
element-directed expression of bFGF in dental pulp stem cells
improve the hypoxic environment by targeting pericytes in SCI rats.
Bioact Mater. 6:2452–2466. 2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Yan M, Schwaederle M, Arguello D, Millis
SZ, Gatalica Z and Kurzrock R: HER2 expression status in diverse
cancers: Review of results from 37,992 patients. Cancer Metastasis
Rev. 34:157–164. 2015.PubMed/NCBI View Article : Google Scholar
|
